Dr Kobayashi will focus on expanding UBC’s operations in Japan with specific oversight on its line of services aimed at improving the reliability of clinical study results. Dr Kobayashi will be joined by several key members of UBC’s management team, including David Miller, who has served as a key scientific leader on several Pan-Asian and multi-national studies involving sites in Japan, Taiwan, Korea, China, Hong Kong, India, Philippines, Singapore, and Thailand.
Dr Kobayashi said: “UBC has demonstrated its ability to improve to quality of data gathered during clinical trials by integrating a wealth of scientific expertise, operational excellence and leading-edge technology. Our new office in Tokyo will facilitate our ability to provide research sponsors with a successful combination of local and international experts to deliver the most cost-effective, high-quality services.”
Catherine Spear, senior vice president at UBC, said: “We believe it is absolutely critical to provide clients with on-the-ground biopharmaceutical research scientists and operations professionals with local knowledge and expertise. The UBC office in Tokyo will help us support our clients’ research projects with local personnel who understand the needs of patients, health care professionals and regulators in this important region. Local knowledge of the Asia-Pacific markets is absolutely essential when we help clients manage research projects that are often very large, complex and supported by significant financial investments.”